It is the first FDA-approved treatment for COPD in more than two decades, according to the release.
“[D]espite maintenance therapy, most patients report grappling with daily symptoms, including breathlessness and persistent coughing,” Michael Wells, MD, associate professor in the division of pulmonary, allergy, and critical care medicine at the University of Alabama Birmingham, said. Dr. Wells was not involved in the drug’s development, but commented on the clinical trial results.
“COPD has a significant impact on both mortality and morbidity in the US, and until today, innovation in inhaled treatment modalities has been limited to combinations of existing treatment classes for over two decades,” Dr. Wells added.
The therapy will be made available during the third quarter of 2024, according to the company.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.